SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 56.70+5.0%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI10/3/2006 2:08:12 PM
   of 507
 
Although NKTR wins, this strikes me as a non-event.

Nektar Therapeutics Issues Statement on Whistle-Blower Proceeding Status

14:01 EDT Tuesday, October 03, 2006

SAN CARLOS, Calif. (Business Wire) -- Nektar Therapeutics (Nasdaq:NKTR) issued a statement regarding the current status of an ongoing administrative proceeding with Ellen Leznik, former corporate counsel, who left Nektar in February 2005. On or about May 11, 2005, Ms. Leznik filed a whistle-blower complaint with the U.S. Department of Labor ("DOL") claiming she had engaged in protected activity under the Sarbanes-Oxley Act during her employment with Nektar. Following applicable procedures, the complaint was referred to the Occupational Safety and Health Administration ("OSHA") of the DOL for investigation.

On or about May 1, 2006, OSHA issued its decision finding in favor of Nektar and against Ms. Leznik and dismissed her complaint. Ms. Leznik currently has an appeal pending before the Office of Administrative Law Judges at the DOL.

"We agree with OSHA's decision in favor of Nektar and believe that Ms. Leznik's action is without merit and therefore we will continue to vigorously defend ourselves in this proceeding," said Gil M. Labrucherie, Chief Compliance Officer of Nektar.

About Nektar

[SNIP]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext